Arena Pharmaceuticals is working to put weight loss in the spotlight. The company is focused on developing biopharmaceutical treatments for cardiovascular, central nervous system, inflammatory, and metabolic diseases. Its lead drug candidate lorcaserin could help assist in weight loss and maintenance in obese patients and patients with type 2 diabetes; however, the drug has had trouble gaining FDA approval. From its manufacturing facility in Switzerland, Arena earns a portion of its revenues as a contract manufacturer for another pharmaceutical company. It also supports its operations with income from R&D partnerships and licensing agreements.